PF-07275315 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).
FDA and DEA call on ADHD drug manufacturers to up production amid ongoing shortages
The US FDA and Drug Enforcement Administration sent a joint letter Tuesday to the public saying that they’re working overtime trying to wrangle shortages of